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Introduction
Septic shock is a frequent cause of death in intensive care
medicine. Possible translocation of bacteria and endotoxins
renders the gastrointestinal tract a crucial factor in this condi-
tion [1]. Reduced perfusion of the splanchnic region because
of centralization results in hypoxia and oedema of the intesti-
nal mucosa. The protective function of the gastrointestinal
tract breaks down and bacteria from the gut enter the blood
and lymph system [2].
Per-oral administration of bovine milk immunoglobulin has
been proved to be effective in the treatment of intestinal
Escherichia coli infection [3]. The biological activity of bacte-
ria and endotoxins was reduced [4,5]. The present study was
conducted to determine whether those findings could be
confirmed in vivo by using three different bovine colostrum
products in animal experiments.
Materials and method
The animal experiments were approved by the Animal Care
Committee (Ethikkommission) of the University Hospital of
Kiel. The colostrum products were provided by the Institut für
Chemie und Physik, Bundesanstalt für Milchforschung, Kiel,
and were not contaminated with lipopolysaccharide.
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A total of 35 male Wistar rats (250–350 g) were anaes-
thetized with ketamine. In order to achieve a degree of
immunosuppression (i.e. an inflammatory state [6]) in the gut
and a higher initial level of plasma endotoxin activity, 80 mg of
type IV carrageenan/kg (Sigma-Aldrich Corp., St Louis, MO,
USA) was injected into the peritoneal cavity. The animals
were randomly assigned to five groups, each comprising
seven animals (Table 1): groups 1, 2 and 3 received 400 mg
iron-saturated bovine colostrum/kg of different compositions
(i.e. types 1–3 bovine colostra); group 4 received a combina-
tion of 400 mg type 2 bovine colostrum/kg plus 80 mg bovine
iron-saturated lactoferrin/kg (Sigma); and group 5 received
400 mg human albumin/kg (control substance).
As albumin, like other proteins, has an unspecific endotoxin-
binding capacity, we wanted to have comparable protein
quantities as referred to a protein commonly used in intensive
care medicine. At the beginning of the 5-hour period of
observation, the first blood samples were taken from the
exposed external jugular vein. Neomycin and bacitracin are
bactericidal and stimulate release of lipopolysaccharide from
E. coli, and their administration results in increasing plasma
endotoxin levels. Therefore, a combination of 5 × 1010
colony-forming units of E. coli/kg (strain O:NT H16 clinical
isolate; University of Kiel, Germany); 10 mg neomycin and
bacitracin/kg; and the group-specific colostrum or albumin
was administered through a per-oral tube (diameter 2 mm).
The tube was fixed in the duodenum by laparotomy (L.N.),
carefully avoiding damage to the efferent biliary tract.
Preliminary investigations without carrageenan had shown
that the maximum endotoxin level in plasma (45 ± 4 EU/dl)
was reached 5 hours after administration of the bacteria/
neomycin–bacitracin suspension. Therefore, the plasma
endotoxin activity was measured hourly for 5 hours. At the
same time points, 2 ml blood was taken from the jugular vein
for culture. The last assessment was followed by laparotomy
(L.N.) and peritoneal lavages with 10 ml endotoxin-free 0.9%
saline solution.
Furthermore, mesenteric lymph nodes from four different
areas of the mesenterium (duodenum and colon) were
resected and homogenized. Bacterial contamination of the
lymph nodes and the hourly blood cultures were examined
using smears on sheep blood agar plates incubated for
48 hours at 37°C. Each lymph node area was examined on
one agar plate and the peritoneal lavage on three agar plates.
Quantity and specification of the bacterial contamination
were not assessed and no anaerobic cultures were per-
formed.
In order to measure the biological endotoxin activity in serum,
we used the modified Limulus amoebocyte/lysate test with a
chromogenic substrate [7]. First, 100 µl of a 1:40 diluted
(0.9% NaCl) plasma sample was heated for 5 min at 80°C.
Then 50 µl of Limulus lysate (Pyroquant 50, ChB: 42-109-
551; Pyroquant Diagnostik GmbH, Mörfelden-Walldorf,
Germany) was added and incubated for 45 min at 37°C.
inally 100 µl of chromogenic substrate (S-2423; Chro-
mogenic Company, Mölndal, Sweden) was added and incu-
bated for 4 min at 37°C. The reaction was stopped with 50 µl
acetic acid (100%) and the extinction was measured by a
photometer at a wavelength of 405 nm. The lower limit of
detection is 3 EU/dl. The baseline plasma endotoxin activity
without application of the bacteria/neomycin–bacitracin sus-
pension was below the lower limit of detection.
Statistical analysis of plasma endotoxin activity was based on
the arithmetic means and standard deviations. Statistical sig-
nificance was evaluated using the nonparametric (distribu-
tion-free method) U test (Wilcoxon and Mann–Whitney).
P < 0.05 was considered statistically significant.
Results
Starting from a control value just above the limit of detection,
there was an approximately linear rise in plasma endotoxin up
to the 4-hour value of 132 ± 29 EU/dl in group 5. The 5-hour
value of 135 ± 24 EU/dl was only slightly higher (Fig. 1). The
bovine colostra administered in groups 1 and 3 significantly
lowered biological activity from the 1-hour value onward
(Table 2). The most effective suppression of biological activity
was observed in group 2, in which the maximum plasma
endotoxin value was 60 ± 20 EU/dl after 3 hours. At the end
of the observation period the value was just 44 ± 10 EU/dl.
Table 1
Composition of bovine colostrum types 1, 2 and 3, and lactoferrin 
Bovine serum 
α-Lacto-albumin  β-Lactoglobulin albumin  Immunoglobulins  LF  Casein  Iron 
Substance (µg/dl) (µg/dl) (µg/dl) (µg/dl) (µg/dl) (µg/dl) (µg/dl)
Type 1 BC 4400 44,400 3600 79,600 1600 ND 200
Type 2 BC 4000 22,400 1600 151,600 ND 80,000 90
Type 3 BC 2800 14,000 2400 145,600 ND 80,000 200
LF ND ND ND ND 80,000 ND 125
BC, bovine colostrum; LF, lactoferrin; ND, not detected.538
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This amounts to a reduction of 67.3% (Fig. 1). In group 4
endotoxin activity was reduced to 27 ± 7 EU/dl (i.e. a
maximum reduction of 80%; Fig. 1).
Bacterial contamination of the peritoneal lavages and lymph
nodes was found to be lowest in experimental group 4
(Table 3). There was no bacterial contamination in any blood
culture after incubation for 48 hours at 37°C.
Discussion
The gastrointestinal tract is of great importance for the
development and prognosis of septicaemia [1,2]. The course
of intensive care patients could be influenced favourably by
selective decontamination of the intestine with local antibiotic
therapy [8]. However, such bactericidal preparations can lib-
erate lipid A fragments from the bacterial cell wall and thus
increase the translocation of endotoxin [9]. It would therefore
appear rational to combine antibiotic with a substance that
inactivates both bacteria and endotoxins [10,11]. An oral
dietetic would be of particular importance in this regard
because plain parenteral nutrition lowers the concentration of
secretory IgA in bile. This weakens immunological resistance
and thus diminishes the barrier function of the intestinal
mucosa [12]. We attempted to demonstrate that bovine
colostrum is better able to inactivate lipopolysaccharide than
albumin.
Administration of bovine colostrum has already proven effica-
cious in treating bacterial and viral enteritis in babies and
infants [13]. Enteral administration of bovine colostrum with a
high immunoglobulin content has been found to reduce peri-
operative translocation of endotoxin from the gastrointestinal
tract [14]. However, it is still unclear which constituents of
bovine colostrum are the crucial biological factors in this ther-
apeutic effect. Neutralization of endotoxins and bacteria has
been reported for immunoglobulins and lactoferrin [5,14].
In our animal experiments, group 2 exhibited the greatest sup-
pression of plasma endotoxin level. This may be due to the
high immunoglobulin content. The reduction in endotoxin
Figure 1
Mean values and standard deviations of plasma endotoxin activity in
experimental group 2 (test 2) and 4 (test 4), and in control group 5
(test 5). *P < 0.05, versus control group; **P < 0.05, versus group 2.
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Table 2
Plasma endotoxin activity
Time (h) Albumin (EU/dl) BC type 1 BC type 3
0 3.0 ± 1.0  2.0 ± 1.0 3.0 ± 1.1 
1 36.0 ± 15.1 18 ± 2.9* 10.0 ± 4.0*
2 69.0 ± 17.2 30.0 ± 5.0* 18.0 ± 2.5*
3 110.0 ±15.7 63.0 ± 21.7* 40.1 ±5.0*
4 132.0 ± 29.3 87.3 ± 26* 62.0 ±10.7*
5 135.0 ± 24.0 75.2 ± 22.8* 52.0 ± 3.0*
Shown are mean values and standard deviations of plasma endotoxin
activity for bovine colostrum (BC) types 1 and 3 (400 mg/kg each) as
compared with the albumin control group (400 mg/kg). Each group
contained seven rats. *P < 0.05, versus control group.
Table 3
Bacterial contamination after 48 hours of incubation of
peritoneal lavage and lymph node specimens
Positive lavage  Positive lymph 
Substance (%) nodes (%)
Albumin 62.5 62.5
Type 1 BC 27.3* 48.0*
Type 2 BC 57.0 55.3
Type 3 BC 25.0* 20.5*
Type 2 BC + 80 mg LF/kg 18.0* 17.0*
Shown are findings with bovine colostrum (BC) types 1, 2 and 3 (400
mg/kg each), and BC type 2 with 80 mg/kg lactoferrin (LF) as
compared with the albumin control group (400 mg/kg). *P < 0.05,
versus control group.539
activity was also significant in group 1. Because that
colostrum contains only half as much immunoglobulin as the
colostra in groups 2 and 3, a distinct effect of lactoferrin in
group 1 is possible. The iron-saturation of the preparations
rules out the possibility that the bacteriostatic effect of lacto-
ferrin derives from removal of iron from the bacterial cell wall.
Therefore, lactoferrin also confers a specific defence mecha-
nism. Intensified elimination of the endotoxin by ‘natural killer
cells’ is conceivable because iron-saturated lactoferrin can
activate these cells. The positive therapeutic effect of combin-
ing type 2 colostrum with 80 mg lactoferrin/kg supports this.
Corresponding effects were evident in the lymph nodes and
peritoneal lavages. The role of systemic and local proinflam-
matory cytokine levels and the significance of immunoglobu-
lins and lactoferrin [4,15,16] in such animal models should be
studied in further research. Because measurement of endo-
toxin in biological fluids is difficult, new techniques such as
the endotoxin activity assay should be considered [17].
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Key messages
• Enteral application of colostrum products is useful in
septic shock
• Colostra with a high amount of lactoferrin can reduce
both endotoxin activity in plasma and bacterial 
contamination of the peritoneal cavity
• Colostra and lactoferrin may help to improve outcomes
in treatment of septic patients